These numbers also show a positive trend towards a prolonged treatment period when compared to other studies, which evaluated historical treatment patterns from 2005 to 2015 in Europe, as well as the US and reported rates between 3 to 22% for third line treatment [ 16 , 26 , 27 ].
← all excerpts
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
1
—
—